RxDoctor Payments Data

Dejan Micic

Gastroenterology · Chicago, ILNPI 1356660203

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Takeda Pharmaceuticals U.S.A., Inc. accounts for 88.6% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $24,478, 7.6 times the $3,210 reported in 2020. Among gastroenterology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$81,481in general payments, 2019–2025

Across 67 payments — averaging $1216.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$72K
  • Ironwood Pharmaceuticals, Inc$7K
  • Johnson & Johnson$2K
  • Tersera Therapeutics LLC$167
  • Nestle Healthcare Nutrition Inc.$106
  • Janssen Scientific Affairs, LLC$68
  • plus $127 from 5 others
$51,739in research payments, 2019–2025

Across 54 payments — averaging $958.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$50K
  • Ferring Pharmaceuticals AS$2K

What the payments were for

  • Consulting fees$35,47544%
  • Speaking & faculty fees$40,82150%
  • Travel & lodging$4,0205%
  • Food & beverage$1,1491%
  • Education$160%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$81,481 in reported general payments places this provider in the 90th percentile of 787 gastroenterology providers in Illinois.

See all gastroenterology providers in Illinois

Medicare billing

Part B allowed, 2024
$79,282
Medicare patients
284
Services billed
512

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GattexTeduglutide13$582,406
CreonLipase/Protease/Amylase11$32,627
Tranexamic Acid14$3,488
Colesevelam Hcl32$2,067
Budesonide DrBudesonide14$1,416
LoperamideLoperamide Hcl25$924
Famotidine61$805
Mirtazapine54$791
Sodium Chloride0.9 % Sodium Chloride28$562
Pantoprazole Sodium47$529
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine16$482
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl24$404
Omeprazole30$318
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl14$284
Nortriptyline Hcl14$177

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gattex$72,179$582,40613 claims
AbbVieCreon$15$32,62711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 787 gastroenterology providers in Illinois.

Other gastroenterology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →